CF PharmTech, Inc. (HKG:2652)

Market Cap	9.24B
Revenue (ttm)	481.31M +23.9%
Net Income	2.77M
EPS	0.01
Shares Out	411.35M
PE Ratio	3,340.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,070,000
Average Volume	642,830
Open	22.16
Previous Close	22.46
Day's Range	21.50 - 22.88
52-Week Range	20.30 - 48.80
Beta	n/a
RSI	39.60
Earnings Date	Mar 30, 2026

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 605
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2652

Financial Performance

In 2025, CF PharmTech's revenue was 432.52 million, a decrease of -28.83% compared to the previous year's 607.75 million. Earnings were 2.49 million, a decrease of -88.22%.

Financial numbers in CNY